Leukemia-inhibitory factor - Neuroimmune modulator of endocrine function

Endocrine Reviews

Volumn 21, Issue 3, 2000, Pages 313-345

  Auernhammer, C J ^a,c   Melmed, S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; PROTEIN INHIBITOR; RECEPTOR SUBUNIT; STAT PROTEIN; SUPPRESSOR FACTOR;

ANIMAL CELL; BONE METABOLISM; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOCRINE FUNCTION; ENERGY BALANCE; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOMODULATION; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NEUROIMMUNOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLACENTA CIRCULATION; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE TYPES;

EID: 0034453195     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.21.3.313     Document Type: Review

References (447)

1. LIF: Not just a leukemia inhibitory factor
2. Interleukin 6 and its receptor: Ten years later
3. GP130 and the interleukin-6 family of cytokines
4. gp130 and the IL-6 family of cytokines: Signaling mechanisms and thrombopoietic activities
5. Leukemia inhibitory factor: Part of a large ingathering family
6. Molecular biology of the leukemia inhibitory factor gene
7. Molecular cloning and expression of cDNA encoding a murine myeloid leukemia inhibitory factor (LIF)
8. Complete sequence of murine myeloid leukaemia inhibitory factor (LIF)
9. Purification of a murine leukemia inhibitory factor from Krebs ascites cells
10. Resolution and purification of three distinct factors produced by Krebs ascites cells which have differentiation-inducing activity on murine myeloid leukemic cell lines
11. Identification of two elements involved in regulating expression of murine leukemia inhibitory factor gene
12. Structural organization of the genes for murine and human leukemia inhibitory factor. Evolutionary conservation of coding and non-coding regions
13. Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia-inhibitory factor
14. Leukaemia inhibitory factor is identical to the myeloid growth factor human interleukin for DA cells
15. The gene for human leukemia inhibitory factor (LIF) maps to 22q12
16. Human differentiation-stimulating factor (leukemia inhibitory factor, human interleukin DA) gene maps distal to the Ewing sarcoma breakpoint on 22q
17. Genomic cloning and heterologous expression of human differentiation-stimulating factor
18. Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor
19. Cross-species comparison of the sequence of the leukemia inhibitory factor gene and its protein
20. Cloning and sequence analysis of the bovine leukemia inhibitory factor (LIF) gene
21. Genetic characterization of the bovine leukaemia inhibitory factor (LIF) gene: Isolation and sequencing, chromosome assignment and microsatellite analysis
22. Molecular cloning and functional analysis of cDNA encoding a rat leukemia inhibitory factor: Towards generation of pluripotent rat embryonic stem cells
23. Cloning of leukemia inhibitory factor (LIF) and its expression in the uterus during embryonic diapause and implantation in the mink (Mustela vison)
24. Localization of the murine leukemia inhibitory factor gene near the centromere on chromosome 11
25. The murine leukemia inhibition factor (LIF) is located on proximal chromosome 11, not chromosome 13
26. Close proximity of the genes for leukemia inhibitory factor and oncostatin M
27. Tandem linkage of genes coding for leukemia inhibitory factor (LIF) and oncostatin M (OSM) on human chromosome 22
28. The genes for oncostatin M (OSM) and leukemia inhibitory factor (LIF) are tightly linked on human chromosome 22
29. Mouse oncostatin M: An immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway
30. Asparagine-linked glycosylation of the rat leukemia inhibitory factor expressed by simian COS7 cells
31. Functions of the N-glycans of rat leukemia inhibitory factor expressed in Chinese hamster ovary cells
32. Delineation of positive and negative control elements within the promoter region of the murine leukemia inhibitory factor (LIF) gene
33. Identification of CpG island at the 5′ end of murine leukemia inhibitory factor gene
34. Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage
35. Complex conserved organization of the mammalian leukemia inhibitory factor gene: Regulated expression of intracellular and extracellular cytokines
36. Human germ cell tumor cell lines express novel leukemia inhibitory factor transcripts encoding differentially localized proteins
37. Leukemia inhibitory factor and interleukin 6 are expressed at very low levels in the normal adult mouse and are induced by inflammation
38. Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: A novel endotoxin-inducible neuro-endocrine interface
39. LIF mRNA expression is transcriptionally regulated in murine bone marrow stromal cells
40. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-α
41. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor α
42. Cytokine-cytokine synergy and protein kinase C in the regulation of lung fibroblast leukemia inhibitory factor
43. Interleukin-4 but not interleukin-10 inhibits the production of leukemia ihibitory factor by rheumatoid synovium and synoviocytes
44. In vitro biosynthesis of leukemia inhibitory factor/human interleukin for DA cells by human endothelial cells: Differential regulation by interleukin-1 α and glucocorticoids
45. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium
46. Interleukin-1 involvement in the induction of leukemia inhibitory factor mRNA expression following axotomy of sympathetic ganglia
47. Leukemia inhibitory factor modulates interleukin-1β-induced activation of the hypothalamo-pituitary-adrenal axis
48. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines
49. Regulatory elements of the leukaemia inhibitory factor (lif) promoter in murine bone marrow stromal cells
50. Leukaemia inhibitory factor expression in cultured rat anterior pituitary is regulated by glucocorticoids
51. Leukaemia inhibitory factor expression is inhibited by glucocorticoids through post-transcriptional mechanisms
52. Neuropoietic cytokines in the hematopoietic fold
53. Cytokine structural taxonomy and mechanisms of receptor engagement
54. Structural biology of cytokines, their receptors, and signaling complexes: Implications for the immune and neuroendocrine circuit
55. Crystallization and preliminary x-ray analysis of leukemia inhibitory factor
56. 1H NMR studies of human leukemia inhibitory factor
57. The crystal structure and biological function of leukemia inhibitory factor: Implications for receptor binding
58. The crystal structure of murine leukemia inhibitory factor
59. Solution dynamics and secondary structure of murine leukemia inhibitory factor: A four-helix cytokine with a rigid CD loop
60. Solution structure of leukemia inhibitory factor
61. 1.9 A crystal structure of interleukin 6: Implications for a novel mode of receptor dimerization and signaling
62. Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing
63. The crystal structure of affinity-matured human growth hormone at 2 A resolution
64. Crystal structure of canine and bovine granulocyte-colony stimulating factor (G-CSF)
65. Crystal structure of the obese protein leptin-E100
66. Localization of functional receptor epitopes on the structure of ciliary neurotrophic factor indicates a conserved, function-related epitope topography among helical cytokines
67. Conversion of the biological specificity of murine to human leukemia inhibitory factor by replacing 6 amino acid residues
68. Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists
69. LIF receptor-gp130 interaction investigated by homology modeling: Implications for LIF binding
70. Structural design and molecular evolution of a cytokine receptor superfamily
71. Signaling by IL-2 and related cytokines: Jak, STATs, and relationship to immmunodeficiency
72. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130
73. Molecular cloning and expression of an IL-6 signal transducer, gp130
74. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo
75. Crystal structure of a cytokine-binding region of gp130
76. Three different cDNAs encoding mouse D-Factor/LIF receptor
77. Molecular basis of the soluble and membrane-bound forms of the murine leukemia inhibitory factor receptor α-chain. Expression in normal, gestating, and leukemia inhibitory factor nullizygous mice
78. Recent evolutionary acquisition of alternative pre-mRNA splicing and 3′ processing regulations induced by intronic B2 SINE insertion
79. Molecular cloning of rat leukemia inhibitory factor receptor alpha-chain gene and its expression during pregnancy
80. The leukemia inhibitory factor receptor (LIFR) gene is located within a cluster of cytokine receptor loci on mouse chromosome 15 and human chromosome 5p12-p13
81. Presence of mRNAs encoding the soluble D-factor/LIF receptor in human choriocarcinoma cells and production of the soluble receptor
82. Identification of an upstream enhancer within a functional promoter of the human leukemia inhibitory factor receptor gene and its alternative promoter usage
83. Functional map of a placenta-specific enhancer of the human leukemia inhibitory factor receptor gene
84. A major binding protein for leukemia inhibitory factor in normal mouse serum: Identification as a soluble form of the cellular receptor
85. Structure of the mouse leukemia inhibitory factor receptor gene: Regulated expression of mRNA encoding a soluble receptor isoform from an alternative 5′-untranslated region
86. Modulation of cartilage proteoglycan metabolism by LIF binding protein
87. Leukemia inhibitory factor (LIF) binding protein attenuates the phlogistic and abolishes the chondral effects of LIF in goat joints
88. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor α-chain in normal human urine and plasma
89. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells
90. Interleukin-6 and soluble interleukin-6 receptor: Direct stimulation of gp130 and hematopoiesis
91. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses
92. Mediation of interleukin-11-dependent biological responses by a soluble form of the interleukin-11 receptor
93. Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and non-hepatic cells
94. Recombinant soluble interleukin-1 (IL-11) receptor α-chain can act as an IL-11 antagonist
95. Released form of CNTF receptor α component as a soluble mediator of CNTF responses
96. Recombinant human CNTF receptor α: Production, binding stoichiometry, and characterization of its activity as a diffusible factor
97. Chromosomal localization of the IL-6 receptor signal transducing subunit, gp130 (IL6ST)
98. Human gp130 transducer chain gene (IL6ST) is localized to chromosome band 5q11 and possesses a pseudogene on chromosome band 17p11
99. Multiple regions within the cytoplasmic domains of the leukemia inhibitory factor receptor and gp130 cooperate in signal transduction in hepatic and neuronal cells
100. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family
101. LIF and OSM directly interact with a soluble form of gp130, the IL-6 receptor signal transducing subunit
102. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130
103. Computational EST database analysis identifies a novel member of the neuropoietic cytokine family
104. Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family
105. The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor
106. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130
107. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmocytoma cells via the common signal transducer, gp130
108. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130
109. Identification of three distinct receptor binding sites of murine interleukin-11
110. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor
111. Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions
112. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes
113. A new type of cytokine receptor antagonist directly targeting gp130
114. An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M
115. The unusual species cross-reactivity of the leukemia inhibitory factor receptor α-chain is determined primarily by the immunoglobulin-like domain
116. Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains
117. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring osm-specific receptor activation
118. Signaling of type II oncostatin M receptor
119. Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6
120. Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice
121. Cloning and characterization of a specific receptor for mouse oncostatin M
122. Reconstitution of the functional mouse oncostatin M (OSM) receptor: Molecular cloning of the mouse OSM receptor β subunit
123. LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor
124. Cross-linking identifies leukemia inhibitory factor-binding protein as a ciliary neurotrophic factor receptor component
125. The tripartite CNTF receptor complex: Activation and signaling involves components shared with other cytokines
126. Identification of ciliary neurotrophic factor (CNTF) residues essential for leukemia inhibitory factor receptor binding and generation of CNTF receptor antagonists
127. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex
128. Signaling of the cardiotrophin-1 receptor. Evidence for a third receptor component
129. Cardiotrophin-1 requires LIFRbeta to promote survival of mouse motoneurons purified by a novel technique
130. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase
131. The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor
132. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling
133. Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6 receptor complex
134. Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6).IL-6 receptor.gp130 complex
135. Theoretical investigation of IL-6 multiprotein receptor assembly
136. Interleukin-6: Structure-function relationships
137. Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction
138. The human IL-11 receptor requires gp130 for signalling: Demonstration by molecular cloning of the receptor
139. Functional expression of soluble human interleukin-11 (IL-11) receptor α and stoichiometry of in vitro IL-11 receptor complexes with gp130
140. High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells
141. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes
142. The mannose 6-phosphate/insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor
143. Mannose 6-phosphate/insulin-like growth factor II receptor mediates internalization and degradation of leukemia inhibitory factor but not signal transduction
144. Growth-hormone-receptor and cytokine-receptor-family signaling
145. Signaling via JAK tyrosine kinases: Growth hormone receptor as a model system
146. STATs and gene regulation
147. The state of the STATs: Recent developments in the study of signal transduction to the nucleus
148. Jak/STAT signaling by cytokine receptors
149. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components
150. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes
151. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes
152. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways
153. Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts
154. Testicular leukemia inhibitory factor (LIF) and LIF receptor mediate phosphorylation of signal transducers and activators of transcription (STAT)-3 and STAT-1 and induce c-fos transcription and activator protein-1 activation in rat Sertoli but not germ cells
155. Highly specific and quantitative activation of STATs in 3T3-L1 adipocytes
156. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses
157. Jak2 is essential for signaling through a variety of cytokine receptors
158. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
159. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction
160. Characterization and binding specificity of the monomeric STAT3-SH2 domain
161. The carboxyl-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation. Involvement of STAT3
162. Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells
163. Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway
164. Leukemia inhibitory factor regulates proopiomelanocortin transcription
165. bFGF and LIF signaling activates STAT3 in proliferating myoblasts
166. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes
167. Activation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-γ in adipocytes
168. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors
169. Cytokine signal transduction in P19 embryonal carcinoma cells: Regulation of Stat3-mediated transactivation occurs independently of p21ras-Erk signaling
170. Members of the family of IL-6-type cytokines activate Stat5a in various cell types
171. Modulation of the activation status of Stat5a during LIF-induced differentiation of M1 myeloid leukemia cells
172. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease
173. Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells
174. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3
175. Essential role of STAT3 for embryonic stem cell pluripotency
176. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line
177. Critical role for STAT3 in murine pituitary ACTH leukemia inhibitory factor (LIF) signaling
178. Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
179. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors
180. Three-dimensional structure of the Stat3beta homodimer bound to DNA
181. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA
182. STAT protein complexes activated by interferon-γ and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties
183. Requirement of serine phosphorylation for formation of STAT-promoter complexes
184. STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase
185. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation
186. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
187. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3
188. SHP-2, SH2-containing protein tyrosine phosphatase-2
189. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
190. Regulation of growth factor-induced signaling by protein-tyrosine-phosphatases
191. Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association
192. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase jak1 and limits acute-phase protein expression
193. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis
194. The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression
195. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells
196. Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2
197. Shp-2 has a positive regulatory role in ES cell differentiation and proliferation
198. The SOCS proteins: A new family of negative regulators of signal transduction
199. Negative regulation of the JAK/STAT pathway
200. The CIS/JAB family: Novel negative regulators of JAK signaling pathways
201. gp130 Sharing cytokines
202. A family of cytokine-inducible inhibitors of signalling
203. Structure and function of a new STAT-induced STAT inhibitor
204. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3
205. Cloning and characterization of novel CIS family genes
206. Pituitary corticotroph SOCS-3: Novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion
207. The Jak-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop
208. A new protein containing an SH2 domain that inhibits JAK kinases
209. CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells
210. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin-6 signaling
211. Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor
212. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling
213. Cytokine-inducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptor-mediated STAT5 signaling
214. Identification of SOCS-3 as a potential mediator of central leptin resistance
215. The role of SOCS-3 in leptin signaling and leptin resistance
216. Repression of IL-4 induced gene expression by IFN-gamma requires Stat1 activation
217. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction
218. A Janus kinase inhibitor, JAB, is an interferon-γ-inducible gene and confers resistance to interferons
219. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities
220. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain
221. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction
222. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: Evidence for an IL-10-induced pathway that is independent of STAT protein activation
223. Specific inhibition of Stag signal transduction by PIAS3
224. Inhibition of Stat1-mediated gene activation by PIAS1
225. Increasing complexity of the Ras signaling pathway
226. Leukemia inhibitory factor and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell line and in sympathetic neuron cultures
227. Raf-1 independent stimulation of mitogen-activated protein kinase by leukemia inhibitory factor in 3T3-L1 cells
228. Involvement of protein kinase C during activation of the mitogen-activated protein kinase cascade by leukemia inhibitory factor. Evidence for participation of multiple signaling pathways
229. Phosphorylation of the human leukemia inhibitory factor (LIF) receptor by mitogen-activated protein kinase and the regulation of LIF receptor function by heterologous receptor activation
230. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes
231. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase
232. Repression of Stat3 activity by activation of mitogen-activated protein kinase
233. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases
234. The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action
235. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1
236. Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling
237. Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines
238. Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association
239. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines
240. Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells
241. Actions of leukaemia inhibitory factor on megakaryocyte and platelet formation
242. The SCL gene product is regulated by and differentially regulates cytokine responses during myeloid leukemic cell differentiation
243. Differential regulation of macrophage differentiation in response to leukemia inhibitory factor/oncostatin-M/interleukin-6: The effect of enforced expression of the SCL transcription factor
244. Murine flt3 ligand protects M1 leukemic cells from LIF-induced differentiation and suppression of self-renewal
245. Expression of the Wilms' tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells
246. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders
247. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects
248. Leukemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation
249. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death
250. Leukemia inhibitory factor can potentiate murine megakaryocyte production in vitro
251. Direct synergistic effects of leukemia inhibitory factor on hematopoietic progenitor cell growth: Comparison with other hematopoietins that use the gp130 receptor subunit
252. Leukemia inhibitory factor upregulates cytokine expression by a murine stromal cell line enabling the maintenance of highly enriched competitive repopulating stem cells
253. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro
254. Hematologic effects of stem cell factor (SCF) and leukemia inhibitory factor (LIF) in vivo: LIF-induced thrombocytosis in SCF-primed mice
255. Cytokine production and function in c-mpl-deficient mice: No physiologic role for interleukin-3 in residual megakaryocyte and platelet production
256. Recombinant human leukemia inhibitory factor induces acute phase proteins and raises blood platelet counts in nonhuman primates
257. In vivo effect of recombinant human leukemia inhibitory factor in primates
258. Influence of leukemia inhibitory factor (LIF) on the survival, proliferation and differentiation of human erythroid progenitor cells. In vitro studies under serum free conditions
259. Overexpression of HOX11 leads to the immortalization of embryonic precursors with both primitive and definitive hematopoietic potential
260. Murine hematopoietic stem cells committed to macrophage/dendritic cell formation: Stimulation by Flk2-ligand with enhancement by regulators using the gp130 receptor chain
261. Upmodulation of multinucleated cell formation in long-term human bone marrow cultures by leukaemia inhibitory factor (LIF)
262. Update of gp130 cytokines in multiple myeloma
263. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias
264. The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells
265. Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology
266. Cytokines which signal through the LIF receptor and their actions in the nervous system
267. The cholinergic neuronal differentiation factor from heart cells is identical to leukemia inhibitory factor
268. Leukemia inhibitory factor induces neurotransmitter switching in transgenic mice
269. CNTF and LIF are not required for the target-directed acquisition of cholinergic and peptidergic properties by sympathetic neurons in vivo
270. A sweat gland-derived differentiation activity acts through known cytokine signaling pathways
271. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway
272. Neural precursor differentiation into astrocytes requires signaling through the leukemia inhibitory factor receptor
273. Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation
274. Astrocyte differentiation mediated by LIF in cooperation with BMP2
275. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300
276. Analysis of neuronal and glial phenotypes in brains of mice deficient in leukemia inhibitory factor
277. Role of leukemia inhibitory factor during mammalian development
278. Preimplantation development of the mammalian embryo and its regulation by growth factors
279. The role of leukemia inhibitory factor and interleukin-6 in human reproduction
280. Leukemia inhibitory factor in human reproduction
281. The role of leukemia inhibitory factor in the establishment of pregnancy
282. Cytokine pleiotropy and redundancy - gp130 cytokines in human implantation
283. Blastocyst implantation depends on maternal expression of leukemia inhibitory factor
284. Effect of immunisation against leukemia inibitory factor on the establishment of pregnancy in sheep
285. Infertility in female mice lacking the receptor for interleukin-11 is due to a defective uterine response to implantation
286. Leukemia inhibitory factor is expressed by the preimplantation uterus and selectively blocks primitive ectoderm formation
287. Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation
288. Leukemia inhibitory factor, LIF receptor, and gp130 in the mouse uterus during early pregnancy
289. Tissue-specific and ontogenic regulation of LIF protein levels determined by quantitative enzyme immunoassay
290. Temporal and spatial expression of leukemia inhibitory factor in rabbit uterus during early pregnancy
291. Presence of leukaemia inhibitory factor and interleukin 6 in porcine uterine secretions prior to conceptus attachment
292. Changes in uterine expression of leukemia inhibitory factor during pregnancy in the western spotted skunk
293. Leukemia inhibitory factor in endometrium during the oestrous cycle, early pregnancy and in ovariectomized steroid-treated ewes
294. Leukemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time
295. Expression of leukemia inhibitory factor in human endometrium and placenta
296. Leukemia inhibitory factor in human endometrium during the menstrual cycle: Cellular origin and action on production of glandular epithelial cell prostaglandin in vitro
297. Leukemia inhibitory factor in human endometrium thoughout the menstrual cycle
298. Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation
299. Localization of leukemia inhibitory factor in human endometrium during the menstrual cycle
300. The role of endometrium in implantation
301. Growth factor/cytokine secretion by a permanent human endometrial cell line with embryotrophic properties
302. The production of leukemia inhibitory factor by human endomtrium: Presence in uterine flushings and production by cells in culture
303. Human decidual cell biosynthesis of leukemia inhibitory factor: Regulation by decidual cytokines and steroid hormones
304. Decidual leukemia inhibitory factor production and action on human chorionic gonadotropin secretion at different stages of gestation in vitro
305. Leukemia inhibitory factor (LIF) production by human decidua and its relationship with pregnancy hormones
306. The presence in human serum of a circulating soluble leukemia
307. Differential hormonal regulation of leukemia inhibitory factor (LIF) in rabbit and mouse uterus
308. Trophic effects of myeloid leukaemia inhibitory factor (LIF) on mouse embryos
309. Progestin-dependent stimulation of the human leukemia inhibitory factor promoter in SKUT-1B uterine tumor cells
310. The effect of various doses of mifepristone on endometrial leukaemia inhibitory factor expression in the midluteal phase - An immunohistochemical study
311. Effect of early luteal phase administration of mifepristone (RU486) on leukaemia inhibitory factor, transforming growth factor beta and vascular endothelial growth factor in the implantation stage endometrium of the rhesus monkey
312. Effect of human chorionic gonadotropin on cytokine production from human endometrial cells in vitro
313. Expression of leukaemia inhibitory factor (LIF) receptor in human placenta: A possible role for LIF in the growth and differentiation of trophoblasts
314. Expression patterns of leukemia inhibitory factor receptor (LIFR) and the gp130 receptor component in rabbit uterus during early pregnancy
315. Complementary tissue-specific expression of LIF and LIF-receptor mRNAs in early mouse embryogenesis
316. Leukaemia inhibitory factor expression in human follicular fluid and ovarian cells
317. Presence of leukemia inhibitory factor and interleukin-12 in human follicular fluid during follicular growth
318. Epidermal growth factor and leukemia inhibitory factor levels in follicular fluid. Association with in vitro fertilization outcome
319. Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos
320. Expression of leukemia inhibitory factor and its receptor in preimplantation embryos
321. Leukemia inhibitory factor produced at the fetomaternal interface stimulates chorionic gonadotropin production: Its possible implication during pregnancy, including implantation period
322. Localization of leukemia inhibitory factor and its receptor in human placenta throughout pregnancy
323. The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: A potential role in human implantation
324. Effect of leukemia inhibitory factor on human cytotrophoblast differentiation along the invasive pathway
325. Myeloid leukemia inhibitory factor maintains the developmental potential of embryonic stem cells
326. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides
327. Establishment of germ-line-competent embryonic stem (ES) cells using differentiation inhibiting activity
328. Differentiation inhibiting activity (DIA/LIF) and mouse development
329. Maintenance of the pluripotential phenotype of embryonic stem cells through direct activation of gp130 signalling pathways
330. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells
331. Effect of Steel factor and leukemia inhibitory factor on murine primordial germ cells in culture
332. Long-term proliferation of mouse primordial germ cells in culture
333. Stem cell factor and leukemia inhibitory factor promote primordial germ cell survival by suppressing programmed cell death (apoptosis)
334. Role of leukemia inhibitory factor and its receptor in mouse primordial germ cell growth
335. Functional requirement of gp130-mediated signaling for growth and survival of mouse primordial germ cells in vitro and derivation of embryonic germ (EG) cells
336. Distinct roles of oncostatin M and leukemia inhibitory factor in the development of primordial germ cells and Sertoli cells in mice
337. Self renewal of embryonic stem cells in the absence of feeder cells and exogenous leukaemia inhibitory factor
338. Paracrine induction of stem cell renewal by LIF-deficient cells: A new ES cell regulatory pathway
339. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions
340. Screening for cytokine messenger ribonucleic acids in purified human decidual lymphocyte populations by the reverse-transcriptase polymerase chain reaction
341. Administration of thymocytes derived from non-pregnant mice induces an endometrial receptive stage and leukaemia inhibitory factor expression in the uterus
342. Endometrial leukemia inhibitory factor (LIF) as a possible cause of unexplained infertility and multiple failures of implantation
343. In-vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women
344. Leukaemia inhibitory factor gene mutations in infertile women
345. Human endometrial leukemia inhibitory factor (LIF) secretion and its relationship to sonographic endometrial appearance
346. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in the human fallopian tube
347. Synthesis and regulation of leukemia inhibitory factor in cultured bovine oviduct cells by hormones
348. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation
349. Immune-neuro-endocrine interactions: Facts and hypotheses
350. Pituitary cytokine and growth factor expression and action
351. The role of cytokines in the normal and neoplastic pituitary
352. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: Actions and mechanisms of action
353. Pathophysiological role of the cytokine network in the anterior pituitary gland
354. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: Identification as leukemia inhibitory factor
355. Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion
356. Stimulatory effect of leukemia inhibitory factor on ACTH secretion of dispersed rat pituitary cells
357. Leukemia inhibitory factor as an intrapituitary mediator of ACTH secretion
358. Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion
359. Regulation of signal transducer, gp130 and the LIF receptor in acute inflammation in vivo
360. Leukemia inhibitory factor (LIF) modulates pro-opiomelanocortin (POMC) gene regulation in stably transfected AtT-20 cells overexpressing LIF
361. Measurement of leukemia inhibitory factor in biological fluids by radioimmunoassay
362. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response
363. Leukemia inhibitory factor (LIF) induces acute adrenocorticotrophic hormone (ACTH) secretion in fetal rhesus macaque primates: A novel dynamic test of pituitary function
364. Interleukin-11 stimulates POMC gene expression and ACTH secretion in corticotroph cells: Evidence for a redundant cytokine network in the HPA axis
365. Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1
366. A common pro-opiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy
367. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia
368. ELISA detection of circulating levels of LIF, OSM, and CNTF in septic shock
369. Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis
370. Sepsis and serum cytokine concentrations
371. Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-α
372. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: Synergistic effect with interleukin 1 and tumor necrosis factor
373. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice
374. Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotropic hormone (ACTH) secretion
375. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction
376. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors
377. Leukemia inhibitory factor induces differentiation of pituitary corticotroph function: An immuno-neuroendocrine phenotypic switch
378. Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function. A model for human pituitary Rathke's cysts
379. Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: Neuro-immune-endocrine modulation of pituitary development
380. Cytokines in the pathogenesis of osteoporosis
381. Immunologic aspects of osteoporosis
382. Interleukins in the control of osteoclast differentiation
383. Cytokines, growth factors and osteoclasts
384. The role of IL-6 type cytokines and their receptors in bone
385. Cytokines, bone remodeling, and estrogen deficiency: A 1998 update
386. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor
387. Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells
388. Serum cytokines in thyrotoxicosis
389. Thyroid hormone stimulates basal and interleukin (IL)-1-induced IL-6 production in human bone marrow stromal cells: A possible mediator of thyroid hormone-induced bone loss
390. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow
391. Leukemia inhibitory factor (LIF): A growth factor with pleiotropic effects on bone biology
392. Leukaemia inhibitory factor and bone cell function
393. Synthesis of colony-stimulating factor (CSF) and differentiation-inducing factor (D-factor) by osteoblastic cells, clone MC3T3-E1
394. Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): Regulation of its production and possible roles in bone metabolism
395. Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA
396. Osteoblasts display receptors for and responses to leukemia-inhibitory factor
397. LIF, but not IL-6, regulates osteoprogenitor differentiation in rat calvaria cell cultures: Modulation by dexamethasone
398. Production of leukemia inhibitory factor mRNA and protein by malignant and immortalized bone cells
399. Increased levels of leukaemia inhibitory factor (LIF) in urine and tissue culture supernatant from human primary bone tumours
400. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction
401. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor
402. Leukemia inhibitory factor binds with high affinity to preosteoblastic RCT-1 cells and potentiates the retinoic acid induction of alkaline phosphatase
403. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells
404. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation
405. Differentiation-inducing factor purified from conditioned medium of mitogentreated spleen cell cultures stimulates bone resorption
406. Leukemia inhibitory factor: A novel bone-active cytokine
407. Leukemia inhibitory factor is mitogenic to osteoblasts
408. The effect of leukemia inhibitory factor on bone in vivo
409. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor
410. A differentiation-inducing factor produced by the osteoblastic cell line MC3T3-E1 stimulates bone resorption by promoting osteoclast formation
411. Leukemia inhibitory factor (LIF) inhibits basal bone resorption in fetal rat long bone cultures
412. Increased osteoclastic differentiation by PMMA particle-associated macrophages. Inhibitory effect by interleukin 4 and leukemia inhibitory factor
413. Culturing of cells from giant cell tumour of bone on natural and synthetic calcified substrata: The effect of leukaemia inhibitory factor and vitamin D3 on the resorbing activity of osteoclast-like cells
414. Osteoclasts are present in gp130-deficient mice
415. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production
416. The role of gp130-mediated signals in osteoclast development: Regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures
417. Oncostatin-M: A new bone active cytokine that activates osteoblasts and inhibits bone resorption
418. Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts
419. Presence of leukemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution
420. Leukemia inhibitory factor suppresses proliferation, alkaline phosphatase activity, and type I collagen messenger ribonucleic acid level and enhances osteopontin mRNA level in murine osteoblast-like (MC3T3E1) cells
421. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage
422. Murine recombinant leukemia inhibitory factor modulates inhibitory effect of 1,25 dihydroxyvitamin D3 on alkaline phosphatase activity in MC3T-E1 cells
423. Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells
424. Recombinant human leukemia inhibitory factor is mitogenic for human bone-derived osteoblast-like cells
425. Leukemia inhibitory factor and oncostatin M influence the mineral phases formed in a murine heterotopic calcification model: A Fourier transform-infrared microspectroscopic study
426. Cytokines and cachexia
427. Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia
428. Wasting in cancer
429. Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia
430. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor
431. Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice
432. Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines
433. Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes
434. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice
435. LIF and CNTF, which share the gp130 transduction system, stimulate hepatic lipid metabolism in rats
436. Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies
437. Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF)
438. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways
439. Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: Possible cellular mechanisms of cancer cachexia
440. Expression and function of members of the cytokine receptor superfamily on breast cancer cells
441. Expression of leukemia inhibitory factor and its receptor in breast cancer: A potential autocrine and paracrine growth regulatory mechanism
442. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells
443. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation
444. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways
445. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells
446. Differential regulation of the human 'leukemia inhibitory factor' (LIF) promoter in T47D and MDA-MB 231 breast cancer cells
447. The mouse mammary tumor cell line MMT060562, produces prostaglandin E2 and leukemia inhibitory factor and supports osteoclast formation in vitro via a stromal cell-dependent pathway